Failure of desmopressin to lower serum sodium or prevent crisis in patients with sickle cell anemia

Blood. 1981 Nov;58(5):892-6.

Abstract

An analogue of arginine vasopressin (desmopressin, DDAVP) was evaluated for production chronic hyponatremia and prevention of sickle cell crisis. With sodium restriction (100 meq Na + / day) and water loading ( greater than 3 liters/day), persistent hyponatremia could not be achieved, nor could crises be prevented or aborted. Patients would not comply with a regimen of lower salt and higher fluid intake. More rigorous treatment might be practical during acute sickle cell crises, and a regimen similar to that used here might be more effective in children, whose renal concentrating mechanisms are still intact.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anemia, Sickle Cell / drug therapy*
  • Arginine Vasopressin / therapeutic use*
  • Deamino Arginine Vasopressin / adverse effects
  • Deamino Arginine Vasopressin / therapeutic use*
  • Erythrocyte Aging
  • Female
  • Humans
  • Hyponatremia / drug therapy
  • Male
  • Osmolar Concentration
  • Pain / etiology
  • Sodium / blood*
  • Urine / analysis

Substances

  • Arginine Vasopressin
  • Sodium
  • Deamino Arginine Vasopressin